BRPI0413091A - compostos de piperidina 1,4-di-substituìdo, seus métodos de preparação, seus medicamentos e usos - Google Patents

compostos de piperidina 1,4-di-substituìdo, seus métodos de preparação, seus medicamentos e usos

Info

Publication number
BRPI0413091A
BRPI0413091A BRPI0413091-0A BRPI0413091A BRPI0413091A BR PI0413091 A BRPI0413091 A BR PI0413091A BR PI0413091 A BRPI0413091 A BR PI0413091A BR PI0413091 A BRPI0413091 A BR PI0413091A
Authority
BR
Brazil
Prior art keywords
disorders
piperidine compounds
preparation methods
npy5
prophylaxis
Prior art date
Application number
BRPI0413091-0A
Other languages
English (en)
Inventor
Antoni Torrens Jover
Josep Mas Prio
Maria Angeles Fisas Escasany
Original Assignee
Esteve Labor Dr
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Esteve Labor Dr filed Critical Esteve Labor Dr
Publication of BRPI0413091A publication Critical patent/BRPI0413091A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C04—CEMENTS; CONCRETE; ARTIFICIAL STONE; CERAMICS; REFRACTORIES
    • C04B—LIME, MAGNESIA; SLAG; CEMENTS; COMPOSITIONS THEREOF, e.g. MORTARS, CONCRETE OR LIKE BUILDING MATERIALS; ARTIFICIAL STONE; CERAMICS; REFRACTORIES; TREATMENT OF NATURAL STONE
    • C04B35/00—Shaped ceramic products characterised by their composition; Ceramics compositions; Processing powders of inorganic compounds preparatory to the manufacturing of ceramic products
    • C04B35/622—Forming processes; Processing powders of inorganic compounds preparatory to the manufacturing of ceramic products
    • C04B35/626—Preparing or treating the powders individually or as batches ; preparing or treating macroscopic reinforcing agents for ceramic products, e.g. fibres; mechanical aspects section B
    • C04B35/63—Preparing or treating the powders individually or as batches ; preparing or treating macroscopic reinforcing agents for ceramic products, e.g. fibres; mechanical aspects section B using additives specially adapted for forming the products, e.g.. binder binders
    • C04B35/632—Organic additives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/56—Nitrogen atoms
    • C07D211/58—Nitrogen atoms attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Manufacturing & Machinery (AREA)
  • Ceramic Engineering (AREA)
  • Pain & Pain Management (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Psychiatry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Structural Engineering (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Materials Engineering (AREA)
  • Cardiology (AREA)
  • Inorganic Chemistry (AREA)
  • Nutrition Science (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Child & Adolescent Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

"COMPOSTOS DE PIPERIDINA 1,4-DI-SUBSTITUìDO, SEUS MéTODOS DE PREPARAçãO, SEUS MEDICAMENTOS E USOS". O objetivo da presente invenção era o de fornecer novos compostos que são adequados em particular como substâncias ativas em medicamentos, preferivelmente em medicamentos para a regulação dos receptores de neuropeptídeo Y, particularmente preferivelmente do receptor do neuropeptídeo Y5 (NPY5) , para a regulação da ingestão de alimentos (consumo de alimentos), preferivelmente para a profilaxia e/ou tratamento de distúrbios da ingestão de alimentos, como obesidade., anorexia, caquexia, bulimia ou diabetes tipo II (não dependente de insulina), para a profilaxia e/ou tratamento de distúrbios do sistema nervoso periférico, distúrbios do sistema nervoso central, ansiedade, depressão, distúrbios cognitivos, preferivelmente distúrbios da memória, doenças cardiovasculares, dor, epilepsia, artrite, síndrome hipertensiva, doenças inflamatórias, doenças imunes e outros distúrbios mediados por NPY5 em animais e mamíferos, incluindo humanos. O referido objetivo foi atingido ao fornecer compostos de piperidina 1,4-di-substituídos de fórmula geral (1) onde os substituintes são definidos na reivindicação 1.
BRPI0413091-0A 2003-07-30 2004-07-29 compostos de piperidina 1,4-di-substituìdo, seus métodos de preparação, seus medicamentos e usos BRPI0413091A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
ES200301813A ES2222833B1 (es) 2003-07-30 2003-07-30 Compuestos piperidinicos 1,4-disustituidos, su preparacion y su uso como medicamentos.
PCT/EP2004/008508 WO2005013988A1 (en) 2003-07-30 2004-07-29 2-`4(phenylamino)-piperidin-1-yl!-n-phenyl-acetamine derivatives and related compounds as neuropeptide y5 (npy5) ligands for the treatement of obesity

Publications (1)

Publication Number Publication Date
BRPI0413091A true BRPI0413091A (pt) 2006-10-03

Family

ID=34130546

Family Applications (2)

Application Number Title Priority Date Filing Date
BRPI0413091-0A BRPI0413091A (pt) 2003-07-30 2004-07-29 compostos de piperidina 1,4-di-substituìdo, seus métodos de preparação, seus medicamentos e usos
BRPI0412860-5A BRPI0412860A (pt) 2003-07-30 2004-07-29 derivados de 2-[4-(2-hidroximetil-fenilamino)-piperidin-1-il]-n-(9h-ca rbazol-3-il)- acetamida e compostos relacionados como ligantes do neuropeptìdeo y5 (npy5) para o tratamento de obesidade

Family Applications After (1)

Application Number Title Priority Date Filing Date
BRPI0412860-5A BRPI0412860A (pt) 2003-07-30 2004-07-29 derivados de 2-[4-(2-hidroximetil-fenilamino)-piperidin-1-il]-n-(9h-ca rbazol-3-il)- acetamida e compostos relacionados como ligantes do neuropeptìdeo y5 (npy5) para o tratamento de obesidade

Country Status (19)

Country Link
US (4) US20070105853A1 (pt)
EP (2) EP1651220B1 (pt)
JP (2) JP2007500169A (pt)
CN (2) CN1829516A (pt)
AR (1) AR045154A1 (pt)
AT (2) ATE348615T1 (pt)
AU (2) AU2004262482A1 (pt)
BR (2) BRPI0413091A (pt)
CA (2) CA2534101A1 (pt)
DE (2) DE602004003829T2 (pt)
ES (3) ES2222833B1 (pt)
MX (2) MXPA06001140A (pt)
MY (1) MY136965A (pt)
NO (2) NO20060553L (pt)
PE (1) PE20050332A1 (pt)
PT (2) PT1651220E (pt)
RU (2) RU2006105792A (pt)
TW (1) TW200510379A (pt)
WO (2) WO2005013988A1 (pt)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9560804B1 (en) 2010-12-15 2017-02-07 Marion Calmer Stalk roll with flutes defining a recess
ES2222833B1 (es) * 2003-07-30 2006-03-01 Laboratorios Del Dr. Esteve, S.A. Compuestos piperidinicos 1,4-disustituidos, su preparacion y su uso como medicamentos.
EP1918281A1 (en) * 2006-11-02 2008-05-07 Laboratorios del Dr. Esteve S.A. Phenylamino-substituted piperidine compounds, their preparation and use as medicaments
WO2008103310A1 (en) 2007-02-16 2008-08-28 Synta Pharmaceuticals Corp. Substituted fused-ring compounds for inflammation and immune-related uses
US20110230497A1 (en) * 2008-11-07 2011-09-22 H. Lundbeck A/S Biologically active amides
CA3191437A1 (en) * 2020-08-11 2022-02-17 Board Of Trustees Of Michigan State University Proteasome enhancers and uses thereof

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997019682A1 (en) 1995-12-01 1997-06-05 Synaptic Pharmaceutical Corporation Aryl sulfonamide and sulfamide derivatives and uses thereof
AU7692996A (en) 1995-12-01 1997-06-27 Ciba-Geigy Ag Receptor antagonists
WO1998024768A1 (en) 1996-12-03 1998-06-11 Banyu Pharmaceutical Co., Ltd. Novel urea derivatives
US6048900A (en) * 1998-02-13 2000-04-11 Bayer Corporation Amide derivatives and methods for using the same as selective neuropeptide Y receptor antagonists
EP0910565A1 (en) * 1997-02-14 1999-04-28 Bayer Corporation Amide derivatives as selective neuropeptide y receptor antagonists
AU6309698A (en) 1997-03-12 1998-09-29 Banyu Pharmaceutical Co., Ltd. Drugs containing aminopyridine derivatives as the active ingredient
US7534857B2 (en) * 1997-12-19 2009-05-19 Centegen, Inc. Methods and compositions for the treatment and prevention of staphylococcal infections
US6187777B1 (en) 1998-02-06 2001-02-13 Amgen Inc. Compounds and methods which modulate feeding behavior and related diseases
EP1119543B1 (en) 1998-10-07 2004-12-15 Ortho-McNeil Pharmaceutical, Inc. N-aralkylaminotetralins as ligands for the neuropeptide y y5 receptor
US6399631B1 (en) * 1999-07-23 2002-06-04 Pfizer Inc. Carbazole neuropeptide Y5 antagonists
WO2001007409A1 (en) * 1999-07-23 2001-02-01 Astrazeneca Uk Limited Carbazole derivatives and their use as neuropeptide y5 receptor ligands
DK1202986T3 (da) * 1999-07-28 2006-02-20 Ortho Mcneil Pharm Inc Amin- og amidderivater som ligander for neuropeptid Y-Y5-receptoren, der er nyttige ved behandlingen af obesitet og andre lidelser
AU769081B2 (en) 1999-08-26 2004-01-15 Bristol-Myers Squibb Company NPY antagonists: spiroisoquinolinone derivatives
SK287726B6 (en) * 2001-07-24 2011-07-06 Richter Gedeon Vegyeszet Carboxylic acid amide derivatives, their preparation, pharmaceutical compositions containing them and process for preparing pharmaceutical compositions
US7067549B2 (en) * 2001-12-31 2006-06-27 Actelion Pharmaceuticals Ag Pyrrolidone carboxamides
ES2193875B2 (es) * 2002-04-09 2005-03-01 Laboratorios Del Dr. Esteve, S.A. Derivados de benzoxazinona, su preparacion y su aplicacion como medicamentos.
ES2228267B1 (es) * 2003-07-30 2006-07-01 Laboratorios Del Dr. Esteve, S.A. Combinacion de sustancias activas conteniendo al menos un compuesto con afinidad por el receptor del neuropeptido y (npy) y al menos un compuesto con afinidad por el receptor 5-ht6.
ES2222833B1 (es) * 2003-07-30 2006-03-01 Laboratorios Del Dr. Esteve, S.A. Compuestos piperidinicos 1,4-disustituidos, su preparacion y su uso como medicamentos.

Also Published As

Publication number Publication date
NO20060605L (no) 2006-02-07
PE20050332A1 (es) 2005-06-12
US20070105853A1 (en) 2007-05-10
WO2005013988A8 (en) 2006-11-09
EP1648458A1 (en) 2006-04-26
TW200510379A (en) 2005-03-16
CN1829516A (zh) 2006-09-06
BRPI0412860A (pt) 2006-10-03
ES2222833B1 (es) 2006-03-01
US20110172270A1 (en) 2011-07-14
CA2534101A1 (en) 2005-02-17
MXPA06001226A (es) 2006-05-15
ES2222833A1 (es) 2005-02-01
EP1651220B1 (en) 2006-12-20
JP2007500162A (ja) 2007-01-11
JP2007500169A (ja) 2007-01-11
CA2534096A1 (en) 2005-02-17
PT1651220E (pt) 2007-03-30
AU2004262482A1 (en) 2005-02-17
NO20060553L (no) 2006-02-02
PT1648458E (pt) 2007-03-30
DE602004003829D1 (de) 2007-02-01
DE602004003829T2 (de) 2007-09-20
DE602004003831D1 (de) 2007-02-01
RU2006105792A (ru) 2007-09-20
CN1832745A (zh) 2006-09-13
EP1648458B1 (en) 2006-12-20
US20100280072A1 (en) 2010-11-04
WO2005013990A1 (en) 2005-02-17
RU2006105711A (ru) 2007-09-20
DE602004003831T2 (de) 2007-10-25
EP1651220A1 (en) 2006-05-03
MXPA06001140A (es) 2006-04-24
AU2004262491A1 (en) 2005-02-17
ATE348615T1 (de) 2007-01-15
MY136965A (en) 2008-12-31
US7888510B2 (en) 2011-02-15
ES2279400T3 (es) 2007-08-16
US20080119516A1 (en) 2008-05-22
ATE348614T1 (de) 2007-01-15
ES2279419T3 (es) 2007-08-16
AR045154A1 (es) 2005-10-19
WO2005013988A1 (en) 2005-02-17

Similar Documents

Publication Publication Date Title
US20210290561A1 (en) Permanently charged sodium and calcium channel blockers as anti-inflammatory agents
KR102605854B1 (ko) 조현병의 치료방법
BRPI0408682A (pt) derivado de benzenossulfonamida, medicamento, uso do derivado de benzenossulfonamida, e, processo para controlar uma doença ou distúrbio inflamatórios ou imuno-reguladores em humanos e animais
DK1104758T3 (da) Acetylenderivativer som anti-inflammatoriske/analgesiske lægemidler
CL43596B (es) Compuestos derivados de pirimidina; composicion farmaceutica; y su uso para tratar o prevenir un trastorno o enfermedad relacionado con la actividad de crth2, tales como asma, rinitis alergica, dermatitis, atopica y conjuntivitis alergica.
BRPI0507790A (pt) composto de pirazolina substituìda, processo para a sua manufatura, medicamentos e seus usos
BR0202547A (pt) Heterociclo-alquilsulfonil-pirazóis como agentes antiinflamatórios/analgésicos
BRPI0909782B8 (pt) composto derivado de azetidina e composição farmacêutica compreendendo dito composto
BRPI0510453A (pt) composto substituìdos com morfolina para o tratamento de distúrbios do sistema nervoso central
CL2008002052A1 (es) Compuestos derivados de pirazol, inhibidores de la 11 beta-hidroxi-esteroide-deshidrogenasa; proceso de preparacion; composicion farmaceutica que comprende a dichos compuestos; y uso para la preparacion de medicamentos para el tratamiento de diabetes, obesidad, trastornos de ingestion de comida o dislipidemia
BR0309083A (pt) Compostos derivados de benzoxazinona, sua preparação e uso como medicamentos
CL2007001006A1 (es) Compuestos derivados de piperidina u 8-aza-biciclo[3.2.1]octano sustituidos; formulacion farmaceutica; producto; y uso para el tratamiento o prevencion de enfermedades tales como diabetes mellitus no insulino dependiente, artritis, obesidad, dislipid
ATE523495T1 (de) Substituierte pyrazolinverbindungen, deren herstellung und verwendung als medikamente
WO2013070659A1 (en) Modulators of opioid receptors and methods of use thereof
BRPI0413091A (pt) compostos de piperidina 1,4-di-substituìdo, seus métodos de preparação, seus medicamentos e usos
CL2004000695A1 (es) Compuestos derivados de 4-fenil piperidina, composicion farmaceutica, util como modulador del receptor opioides, para tratar sindrome de intestino irritable, adiccion o dependencia de drogas, depresion, ansiedad, esquizofrenia, trastornos de la alime
BRPI0508724A (pt) derivados do fenilaminoetanol como agonistas do receptor beta2
MX2009005507A (es) Derivados de espiro-piperidina.
WO2008074935A3 (fr) Compositions biologiquement actives, procédé pour leur obtention, et applications biologiques
BRPI0415538A (pt) utilização de um derivado do pirazol para o preparo de medicamento úteis na prevenção e no tratamento das dislipidemias e das doenças associadas às dislipidemias e/ou à obesidade
BR0116653A (pt) Medicamento contendo uma poliamina como substância ativa
RU2738648C2 (ru) Применение соединения для лечения хронической тревоги или острой тревоги
BRPI0518789A2 (pt) formulaÇço farmacÊutica, processo para preparar uma formulaÇço farmacÊutica, produto, e, cÁpsula ou tablete
BRPI0518786A2 (pt) formulaÇço farmacÊutica, processo para preparar uma formulaÇço farmacÊutica, produto, e, cÁpsula ou tablete
BRPI0909824A2 (pt) 2-aminoquinolinas

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]